Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 14/20 | 0.64 |
| ▸ | CA2 | P00918 | 14/20 | 0.64 |
| ▸ | CA4 | P22748 | 14/20 | 0.64 |
| ▸ | CA7 | P43166 | 14/20 | 0.64 |
| ▸ | CA9 | Q16790 | 14/20 | 0.64 |
| ▸ | CA1 | P00915 | 13/20 | 0.64 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | ABCC8 | Q09428 | 1/20 | 0.38 |
| ▸ | KCNJ11 | Q14654 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16277684 | 0.75 | CA12 (1.00) | CA12CA2CA4CA7CA9 | |
| SCHEMBL29766350 | 0.75 | CA12 (1.00) | CA12CA2CA4CA7CA9 | |
| SCHEMBL8492205 | 0.75 | CA12 (1.00) | CA12CA2CA4CA7CA9 | |
| SCHEMBL29766352 | 0.74 | CA12 (1.00) | CA12CA2CA4CA7CA9 | |
| SCHEMBL3760039 | 0.74 | CA12 (1.00) | CA12CA2CA4CA7CA9 | |
| SCHEMBL8494657 | 0.73 | CA12 (0.97) | CA12CA2CA4CA7CA9 | |
| SCHEMBL16285385 | 0.73 | PTK2 (0.44) | CA2CA9PARP1SMN1; SMN2HSD17B10 | |
| SCHEMBL7902885 | 0.72 | PARP1 (0.44) | CA12CA2CA4CA7CA9 | |
| SCHEMBL29766441 | 0.71 | CA12 (1.00) | CA12CA2CA4CA7CA9 | |
| SCHEMBL3493374 | 0.71 | CA12 (1.00) | CA12CA2CA4CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7517875-B2 | Piperidine derivatives having CCR3 antagonism | TEIJIN LIMITED (JP) | 2009-04-14 | — | — | US | disclosed |
| US-20070032525-A1 | Piperidine derivatives having ccr3 antagonism | TEIJIN LIMITED, A JAPANESE BODY CORPORATE (JP) | 2007-02-08 | — | — | US | disclosed |
| EP-1502916-A1 | PIPERIDINE DERIVATIVES HAVING CCR3 ANTAGONISM | TEIJIN LIMITED (JP) | 2005-02-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032525-A1 | Piperidine derivatives having ccr3 antagonism | CCR3, CCR1, CCR4 | CA12 3636/4885CA2 1068/4885CA4 1533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.